This website uses cookies to ensure you have the best user experience. By continuing to use this website, you consent to our use of cookies. For more information, read our privacy policy.
This is a test.
ES2 trial: combining a PARP inhibitor and apoptosis sensitizer
This is a test.
Tumour testing and ovarian cancer drug prediction program
This is a test.
Phase II clinical trial of CX5461 at the time of disease progression on a PARP inhibitor
This is a test.
Exploring and exploiting aberrant RBX1 expression in high-grade serous ovarian cancer
This is a test.
Preventing ovarian cancer through the expansion of opportunistic salpingectomy
This is a test.
Understanding the experience of previvors receiving care at a specialized centre
This is a test.
CHARM Early Detection Clinical Trial
This is a test.
NEOCATS trial: Targeting the targets with a combination of three treatments
This is a test.
Re-VOLVE trial: using genomics to make treatment decisions after a PARP inhibitor
